| ||Audit Committee||Compensation Committee||Nominating & Corporate Governance Committee||Science & Technology Committee|
|Steven M. Altschuler, M.D. |
|Steven M. Altschuler, M.D.|
Senior Vice President of Health Affairs, University of Miami CEO, UHealth-University of Miami Health System
Dr. Steven M. Altschuler, is Senior Vice President of Health Affairs at the University of Miami and Chief Executive Officer of UHealth-University of Miami Health System. He was named to the position in November 2015.
Steve is responsible for the strategic and operational leadership of the University’s clinical delivery system, which includes the University’s hospitals, faculty practice plan and clinics. As South Florida’s only academic-based health system, UHealth combines patie...
|Lars Ekman, M.D., Ph.D. |
|Lars Ekman, M.D., Ph.D.|
Former President of Research and Development, Elan
Dr. Lars Ekman has 30 years of experience in senior executive, scientific and clinical functions. He has served as executive partner at Sofinnova Ventures since 2008, lending his extensive expertise in the life sciences industry to the investment team in driving new companies toward success.
Prior to joining Sofinnova Ventures, Lars was president of research and development at Elan. He is credited with advancing Elan’s drug discovery pipeline during his tenure, and under his leadersh...
|Anand Mehra, M.D. |
|Anand Mehra, M.D.|
General Partner, Sofinnova Ventures
Dr. Anand Mehra joined Sofinnova Ventures in 2007 and is focused on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Aclaris and Prothena, and he played a key role in the firm’s investments in SarCode (acquired by Shire), Preglem (acquired by Gedeon Richter) and Amarin. In addition to Spark Therapeutics, Anand is cur...
|| || ||
|Vin Milano |
Chief Executive Officer, Idera Pharmaceuticals; Former President, Chief Executive Officer and Chairman, ViroPharma
Vin Milano is chief executive officer of Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases. Prior to Idera, Vin was president, chief executive officer and chairman of the board of directors of ViroPharma Incorporated (acquired by Shire Pharmaceuticals in January 2014), which focused on bringing innovative therapies to market for serious, unmet medical needs. ViroPharma’s lead product was Cinryze®, approved and ...
|| || |
|Elliott Sigal, M.D., Ph.D. |
|Elliott Sigal, M.D., Ph.D.|
Former Director, Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb
Dr. Elliott Sigal has over 25 years of combined experience in medicine, research and executive management. Most recently, he served as director, executive vice president and chief scientific officer and president of R&D at Bristol-Myers Squibb from 2004 until 2013. Elliott was a principal architect of the company’s successful biopharma transformation strategy, with a focus on innovative therapies for unmet medical needs, and was instrumental in increasing R&D productivity, developing the comp...
Lota Zoth, CPA, has served in senior financial roles in a variety of commercial-stage companies over a 30-year career, including serving as chief financial officer for MedImmune before its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Lota served as senior vice president, corporate controller and principal accounting officer at PSINet Inc., vice president, corporate controller and chief accounting officer at Sodexho Marriott Services, Inc., Marriott International and...
|| || || |
|Katherine A. High, M.D. |
|Katherine A. High, M.D.|
Co-Founder, President and Chief Scientific Officer
Dr. Kathy High, an accomplished hematologist with a longstanding interest in gene therapy for genetic disease, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to AAV vectors in a variety of target tissues. Kathy’s work has evolved to encompass c...
| || || ||